Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Amicus Therapeutics (FOLD) over the last 16 years, with Dec 2024 value amounting to -$29.3 million.

  • Amicus Therapeutics' Net Cash Flow rose 12.04% to $33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$59.7 million, marking a year-over-year decrease of 224.19%. This contributed to the annual value of -$29.3 million for FY2024, which is 132.36% down from last year.
  • According to the latest figures from FY2024, Amicus Therapeutics' Net Cash Flow is -$29.3 million, which was down 132.36% from $90.7 million recorded in FY2023.
  • Amicus Therapeutics' 5-year Net Cash Flow high stood at $90.7 million for FY2023, and its period low was -$81.7 million during FY2022.
  • Over the past 3 years, Amicus Therapeutics' median Net Cash Flow value was -$29.3 million (recorded in 2024), while the average stood at -$6.8 million.
  • Per our database at Business Quant, Amicus Therapeutics' Net Cash Flow skyrocketed by 452.52% in 2021 and then plummeted by 192.51% in 2022.
  • Yearly analysis of 5 years shows Amicus Therapeutics' Net Cash Flow stood at $16.0 million in 2020, then surged by 452.52% to $88.3 million in 2021, then plummeted by 192.51% to -$81.7 million in 2022, then soared by 210.92% to $90.7 million in 2023, then slumped by 132.36% to -$29.3 million in 2024.